Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 137

  • Filters activated: AIDS. Clear all to show 7854 items.
1.

First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1.

Mahipal A, Ejadi S, Gnjatic S, Kim-Schulze S, Lu H, Ter Meulen JH, Kenney R, Odunsi K.

Cancer Immunol Immunother. 2019 May 8. doi: 10.1007/s00262-019-02331-x. [Epub ahead of print]

PMID:
31069460
2.

A Mixed-Methods Study Examining Adherence to and Acceptability of Intravaginal Rings for HIV Prevention: Behavioral Results of MTN-027.

Bauermeister JA, Golinkoff JM, Carballo-Diéguez A, Giguere R, López D, Hoesley CJ, Chen BA, Anderson P, Dezzutti CS, Strizki J, Sprinkle C, Heard F, Hall W, Jacobson C, Berthiaume J, Mayo A, Richardson BA, Piper J; Microbicide Trials Network 027 Study Team.

AIDS Behav. 2019 Mar 15. doi: 10.1007/s10461-019-02457-0. [Epub ahead of print]

PMID:
30877580
3.

Tenofovir gel for prevention of herpes simplex virus type-2 acquisition: findings from the VOICE Trial.

Marrazzo JM, Rabe L, Kelly C, Richardson B, Deal C, Schwartz JL, Chirenje ZM, Piper J, Morrow RA, Hendrix CW, Marzinke MA, Hillier SL; VOICE Study Team.

J Infect Dis. 2019 Feb 11. doi: 10.1093/infdis/jiz045. [Epub ahead of print]

PMID:
30753642
4.

Pharmacokinetics of Dapivirine Transfer into Blood Plasma, Breast Milk, and Cervicovaginal Fluid of Lactating Women Using the Dapivirine Vaginal Ring.

Noguchi LM, Hoesley C, Kelly C, Scheckter R, Bunge K, Nel A, Marzinke MA, Hendrix CW, Dezzutti CS, Hillier SL, Bogen DL, Piper JM, Beigi RH.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e01930-18. doi: 10.1128/AAC.01930-18. Print 2019 Mar.

PMID:
30602513
5.

Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy.

Makanani B, Balkus JE, Jiao Y, Noguchi LM, Palanee-Phillips T, Mbilizi Y, Moodley J, Kintu K, Reddy K, Kabwigu S, Jeenariain N, Harkoo I, Mgodi N, Piper J, Rees H, Scheckter R, Beigi R, Baeten JM.

J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):566-572. doi: 10.1097/QAI.0000000000001861.

PMID:
30383589
6.

Prevalence and determinants of anal human papillomavirus infection in men who have sex with men and transgender women.

Cranston RD, Carballo-Diéguez A, Gundacker H, Richardson BA, Giguere R, Dolezal C, Siegel A, KunjaraNaAyudhya RP, Gomez K, Piper JM, Lama JR, McGowan I; MTN-017 Protocol Team.

Int J STD AIDS. 2019 Feb;30(2):154-162. doi: 10.1177/0956462418797864. Epub 2018 Oct 18.

PMID:
30336747
7.

An ethnobotanical survey and antifungal activity of Piper guineense used for the treatment of fungal infections in West-African traditional medicine.

Mgbeahuruike EE, Holm Y, Vuorela H, Amandikwa C, Fyhrquist P.

J Ethnopharmacol. 2019 Jan 30;229:157-166. doi: 10.1016/j.jep.2018.10.005. Epub 2018 Oct 15.

PMID:
30336302
8.

Trajectory of use over time of an oral tablet and a rectal gel for HIV prevention among transgender women and men who have sex with men.

Leu CS, Giguere R, Bauermeister JA, Dolezal C, Brown W 3rd, Balán IC, Richardson BA, Piper JM, Lama JR, Cranston RD, Carballo-Diéguez A.

AIDS Care. 2019 Mar;31(3):379-387. doi: 10.1080/09540121.2018.1533223. Epub 2018 Oct 14.

PMID:
30318905
9.

Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048.

Liu AY, Zhang J, Anderson PL, Wagner T, Pan Z, Peda M, Gomez K, Beamer M, Jacobson C, Strizki J, Dezzutti CS, Piper JM; MTN-028 Protocol Team for the Microbicide Trials Network.

Clin Infect Dis. 2018 Oct 4. doi: 10.1093/cid/ciy652. [Epub ahead of print]

PMID:
30289444
10.

Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings.

Hoesley CJ, Chen BA, Anderson PL, Dezzutti CS, Strizki J, Sprinkle C, Heard F, Bauermeister J, Hall W, Jacobson C, Berthiaume J, Mayo A, Gundacker H, Richardson-Harman N, Piper J; Microbicide Trials Network 027 Study Team.

Clin Infect Dis. 2018 Oct 4. doi: 10.1093/cid/ciy653. [Epub ahead of print]

PMID:
30289435
11.

Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.

Justman JE, Nair GL, Hendrix CW, Piper JM, Marzinke MA, Dai JY, Pan Z, Galaska B, Levy L, Schwartz JL, Balar B, Kunjara Na Ayudhya RP, Mushamiri I, McGowan I, Dezzutti CS; MTN-014 Study Team.

J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):175-182. doi: 10.1097/QAI.0000000000001655.

PMID:
29767639
12.

Local immune response to larvae of Rhipicephalus microplus in Santa Gertrudis cattle.

Constantinoiu CC, Lew-Tabor A, Jackson LA, Jorgensen WK, Piper EK, Mayer DG, Johnson L, Venus B, Jonsson NN.

Parasite Immunol. 2018 Apr;40(4):e12515. doi: 10.1111/pim.12515. Epub 2018 Feb 15.

13.

Implementation of a prospective pregnancy registry for antiretroviral based HIV prevention trials.

Mhlanga FG, Noguchi L, Balkus JE, Kabwigu S, Scheckter R, Piper J, Watts H, O'Rourke C, Torjesen K, Brown ER, Hillier SL, Beigi R.

HIV Clin Trials. 2018 Feb;19(1):8-14. doi: 10.1080/15284336.2017.1411419. Epub 2017 Dec 21.

14.

A strain-specific multiplex RT-PCR for Australian rabbit haemorrhagic disease viruses uncovers a new recombinant virus variant in rabbits and hares.

Hall RN, Mahar JE, Read AJ, Mourant R, Piper M, Huang N, Strive T.

Transbound Emerg Dis. 2018 Apr;65(2):e444-e456. doi: 10.1111/tbed.12779. Epub 2017 Dec 10.

PMID:
29226567
15.

Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men.

Carballo-Diéguez A, Giguere R, Dolezal C, Leu CS, Balán IC, Brown W 3rd, Rael C, Richardson BA, Piper JM, Bekker LG, Chariyalertsak S, Chitwarakorn A, Gonzales P, Holtz TH, Liu A, Mayer KH, Zorrilla CD, Lama JR, McGowan I, Cranston RD; MTN-017 Protocol Team.

AIDS Behav. 2017 Dec;21(12):3336-3345. doi: 10.1007/s10461-017-1969-1.

16.

Rapid diagnosis of new and relapse tuberculosis by quantification of a circulating antigen in HIV-infected adults in the Greater Houston metropolitan area.

Fan J, Zhang H, Nguyen DT, Lyon CJ, Mitchell CD, Zhao Z, Graviss EA, Hu Y.

BMC Med. 2017 Nov 1;15(1):188. doi: 10.1186/s12916-017-0952-z.

17.

Brief Participant-Centered Convergence Interviews Integrate Self-Reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017.

Balán IC, Giguere R, Brown W 3rd, Carballo-Diéguez A, Horn S, Hendrix CW, Marzinke MA, Ayudhya RPKN, Patterson K, Piper JM, McGowan I, Lama JR, Cranston RD; MTN-017 Protocol Team.

AIDS Behav. 2018 Mar;22(3):986-995. doi: 10.1007/s10461-017-1955-7.

18.

Plasma Levels of Complement Factor I and C4b Peptides Are Associated with HIV Suppression.

Wu B, Ouyang Z, Lyon CJ, Zhang W, Clift T, Bone CR, Li B, Zhao Z, Kimata JT, Yu XG, Hu Y.

ACS Infect Dis. 2017 Dec 8;3(12):880-885. doi: 10.1021/acsinfecdis.7b00042. Epub 2017 Sep 15.

19.

High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.

Carballo-Diéguez A, Balán IC, Brown W 3rd, Giguere R, Dolezal C, Leu CS, Marzinke MA, Hendrix CW, Piper JM, Richardson BA, Grossman C, Johnson S, Gomez K, Horn S, Kunjara Na Ayudhya RP, Patterson K, Jacobson C, Bekker LG, Chariyalertsak S, Chitwarakorn A, Gonzales P, Holtz TH, Liu A, Mayer KH, Zorrilla C, Lama J, McGowan I, Cranston RD.

PLoS One. 2017 Jul 27;12(7):e0181607. doi: 10.1371/journal.pone.0181607. eCollection 2017.

20.

Accurate virus quantitation using a Scanning Transmission Electron Microscopy (STEM) detector in a scanning electron microscope.

Blancett CD, Fetterer DP, Koistinen KA, Morazzani EM, Monninger MK, Piper AE, Kuehl KA, Kearney BJ, Norris SL, Rossi CA, Glass PJ, Sun MG.

J Virol Methods. 2017 Oct;248:136-144. doi: 10.1016/j.jviromet.2017.06.014. Epub 2017 Jun 29.

Supplemental Content

Loading ...
Support Center